Manufacturer or GPO Program year 2025 Source: CMS Open Payments

Kyowa Kirin Services Ltd

Great Britain (UK)

CMS manufacturer 100000231808

Open in the dashboard

General payments

$104,975

51 payments

Research payments

$1,280,965

158 payments

Ownership & investment interest

$0

None reported

Through program year 2025, Kyowa Kirin Services Ltd reported paying $104,975 in general payments and $1,280,965 in research payments to U.S. physicians, teaching hospitals and other recipients.

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

11 rows
Year Kind Amount Payments
2025 General $20,222 9
2025 Research $642,033 32
2024 General $24,713 18
2024 Research $197,067 88
2023 General $12,999 7
2023 Research $132,428 35
2022 General $5,750 4
2022 Research $309,438 3
2021 General $20,764 5
2020 General $6,500 2
2019 General $14,027 6

Breakdown

Top recipients General payments · program year 2025
  1. Maria Diaz-Gonzalez Ferris Nephrology · Chapel Hill, NC $10,115 4 payments
  2. Kathryn Dahir Endocrinology, Diabetes & Metabolism · Nashville, TN $10,050 4 payments
  3. Youn Hee Kim Dermatology · Stanford, CA $56 1 payment
Top research recipients Research payments · program year 2025
  1. Medical College Of Wisconsin $588,029 7 payments
  2. University Of Washington Med Ctr Teaching hospital · WA $28,877 5 payments
  3. The Johns Hopkins University School Of Medicine $16,041 10 payments
  4. Washington University School Of Medicine $4,080 1 payment
  5. Inova Health Care Services $3,221 2 payments
  6. Inova Fairfax Hospital Teaching hospital · VA $1,304 2 payments
  7. The Trustees Of Columbia University In The City Of New York $482 5 payments
Products the payments named General payments · program year 2025
  1. Crysvita fibroblast growth factor 23 (FGF23) blocking antibody $20,165 100% · 2 recipients
  2. Poteligeo Monoclonal Antibody $56 <1% · 1 recipient

Each share is of this company’s general payments naming a product in 2025. A payment can name up to five products, so these amounts overlap.

Specialties paid General payments · program year 2025
  1. Nephrology Internal Medicine $10,115 50% · 1 practitioner
  2. Endocrinology, Diabetes & Metabolism Internal Medicine $10,050 50% · 1 practitioner
  3. Dermatology $56 <1% · 1 practitioner

Each share is of this company’s general payments to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2025
  1. North Carolina $10,115 50% · 1 recipient
  2. Tennessee $10,050 50% · 1 recipient
  3. California $56 <1% · 1 recipient

Each share is of this company’s general payments in 2025 where a state was reported.

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $68,284 21 payments
  2. Travel and Lodging $22,923 16 payments
  3. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $5,898 1 payment
  4. Education $4,400 1 payment
  5. Honoraria $3,006 2 payments
  6. Food and Beverage $464 10 payments
Companies with a similar name General payments · program years 2019–2025
  1. Kyowa Kirin, Inc. NJ, United States $12,729,295
  2. Kyowa Hakko Kirin Co., Ltd Japan $483,036
  3. Kyowa Kirin Pharmaceutical Development, Inc NJ, United States $120,167

Grouped by name only. CMS publishes no corporate ownership, so a shared name does not mean a shared parent.

51 general · 158 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers of drugs, devices and biologicals, and group purchasing organisations, are required to report the payments and transfers of value they make to physicians and teaching hospitals. This page shows what this company reported.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record